Brinter has teamed up with Canadian start-up Axolotl Biosciences and plans to test Axolotl’s novel fibrin-based neurobioink for research and development purposes. This beta product has been specifically formulated for the extrusion bioprinting of neural tissue. There is an apparent lack of appropriate tools to predict how, for example, drug candidates act on neural tissue. Thus, a bioink dedicated to bioprinting neural tissue models for drug testing would be highly needed.
BioTuesdays has recently featured Axolotl Biosciences and its CEO, Stephanie Willerth, on their website, where more information about the development of this research-grade bioink for long-term culture of 3D neural tissue can be found.